Mortality and Other Important Diabetes-Related Outcomes With Insulin vs Other Antihyperglycemic Therapies in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
CONTEXT: The safety of insulin in the treatment of type 2 diabetes mellitus (T2DM) has recently undergone scrutiny. OBJECTIVE: The objective of the study was to characterize the risk of adverse events associated with glucose-lowering therapies in people with T2DM. DESIGN AND SETTING: This was a retrospective cohort study using data from the UK General Practice Research Database, 2000-2010. PATIENTS: Patients comprised 84 622 primary care patients with T2DM treated with one of five glucose-lowering regimens: metformin monotherapy, sulfonylurea monotherapy, insulin monotherapy, metformin plus sulfonylurea combination therapy, and insulin plus metformin combination therapy. There were 105 123 exposure periods. MAIN OUTCOME MEASURES: The risk of the first major adverse cardiac event, first cancer, or mortality was measured. Secondary outcomes included these individual constituents and microvascular complications. RESULTS: In the same model, and using metformin monotherapy as the referent, the adjusted hazard ratio (aHR) for the primary end point was significantly increased for sulfonylurea monotherapy (1.436, 95% confidence interval [CI] 1.354-1.523), insulin monotherapy (1.808, 95% CI 1.630-2.005), and insulin plus metformin (1.309, 95% CI 1.150-1.491). In glycosylated hemoglobin/morbidity subgroups, patients treated with insulin monotherapy had aHRs for the primary outcome ranging from 1.469 (95% CI 0.978-2.206) to 2.644 (95% CI 1.896-3.687). For all secondary outcomes, insulin monotherapy had increased aHRs: myocardial infarction (1.954, 95% CI 1.479-2.583), major adverse cardiac events (1.736, 95% CI 1.441-2.092), stroke (1.432, 95% CI 1.159-1.771), renal complications (3.504, 95% CI 2.718-4.518), neuropathy (2.146, 95% CI 1.832-2.514), eye complications (1.171, 95% CI 1.057-1.298), cancer (1.437, 95% CI 1.234-1.674), or all-cause mortality (2.197, 95% CI 1.983-2.434). When compared directly, aHRs were higher for insulin monotherapy vs all other regimens for the primary end point and all-cause mortality. CONCLUSIONS: In people with T2DM, exogenous insulin therapy was associated with an increased risk of diabetes-related complications, cancer, and all-cause mortality. Differences in baseline characteristics between treatment groups should be considered when interpreting these results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Insulin therapy has raised similar concerns with respect to cardiovascular safety and has been associated with adverse cardiovascular outcomes and mortality in observational studies.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [206]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Standards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125 · cited 8×
“670 Currie et al Clinical Outcomes of Treatment With Insulin J Clin Endocrinol Metab, February 2013, 98(2):668–677”
InfluentialThe National Institute for Clinical Excellence
(2001) · Nursing Management · doi:10.7748/nm.8.2.39.s15 · Cited by 3,876
Basevi, V., Di Mario, S., Morciano, C., Nonino, F., & Magrini, N. (2011) · Diabetes Care · doi:10.2337/dc11-0174 · Cited by 3,055
Standards of medical care in diabetes—2011
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s011 · Cited by 2,880
Basal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636 · cited 1×
“3 mmol/L with insulin glargine vs usual care over an estimated five-year treatment period in people with established cardiovascular disease coupled with glucose intolerance or early T2DM (29).”
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124 · cited 2×
“Indeed, endogenous hyperinsulinemia has been linked to an increase in cancer incidence in people without diabetes (30), whereas epidemiological data have linked exogenous insulin therapy with an increased cancer incidence in people with T2DM (22).”
BackgroundSelf-citationGerstein, H. C., Miller, M., & Byington, R. P. (2010) · Cited by 981
Cited by
Items 101–200 of 203
Bala, C. G., Rusu, A., Ciobanu, D. M., Craciun, A. E., & Román, G. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s162086 · Cited by 12
Szymczak-Pajor, I., Fleszar, K., Kasznicki, J., Gralewska, P., & Śliwińska, A. (2021) · Toxicology in Vitro · doi:10.1016/j.tiv.2021.105128 · Cited by 13
AKINBOBOYE, O. J., Williams, J. S., Garacci, E., & Egede, L. E. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.09.022 · Cited by 13
Kim, S. S., Kim, I. J., Lee, K. J., Park, J. H., Kim, Y. I., Lee, Y. S., Chung, S. C., & Lee, S. J. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12432 · Cited by 12
Hsiao, P.-J., Wu, K.-L., Chiu, S.-H., Chan, J., Lin, Y., Wu, C., Wu, C., Kao, S., Fang, T., Lin, S., et al. (2016) · Clinical and Experimental Nephrology · doi:10.1007/s10157-016-1330-4 · Cited by 12
Wong, C. K. H., Man, K. K. C., Chan, E. W., Wu, T., Tse, E. T. Y., Wong, I. C. K., & Lam, C. L. K. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001346 · Cited by 10
Management of Type 2 Diabetes Mellitus
Salti, I. S. (2014) · The Endocrine Society eBooks · doi:10.1210/mtp3.9781936704835.ch16 · Cited by 11
Wong, C. K. H., Man, K. K. C., Shi, M., Chan, E. W., Ho, C. W., Tse, E. T. Y., Wong, I. C. K., & Lam, C. L. K. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1002999 · Cited by 11
All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine
Strandberg, A. Y., Hoti, F. J., Strandberg, T. E., Christopher, S., Haukka, J. K., & Korhonen, P. A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151910 · Cited by 13
Insulin resistance and cardiovascular outcomes in the ORIGIN trial
Gerstein, H. C., Ferrannini, E., Riddle, M. C., Yusuf, S., & ORIGIN Trial Investigators (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13112 · Cited by 13
Mayer, O., Bruthans, J., Seidlerová, J., Karnosová, P., Vaněk, J., Hronová, M., Gelžinský, J., Cvíčela, M., Wohlfahrt, P., Cífková, R., et al. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.07.018 · Cited by 10
Kuo, S., Yang, C., Wu, J., & Ou, H. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13525 · Cited by 11
Novel Approaches to the Management of Diabetes Mellitus in Patients with Coronary Artery Disease
Oikonomou, E. K., Xenou, M., Zakynthinos, G. Ε., Tsaplaris, P., Lampsas, S., Bletsa, E., Gialamas, I., Kalogeras, K. I., Goliopoulou, A., Gounaridi, M. I., et al. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230703161058 · Cited by 12
Anagnostis, P. G., Siolos, P., Christou, K., Gkekas, N. K., Kosmidou, N., Athyros, V. G., & Karagiannis, A. I. (2018) · HORMONES · doi:10.1007/s42000-018-0017-5 · Cited by 10
Alkharaiji, M. A., Anyanwagu, U., Donnelly, R., & IDRIS, I. R. (2020) · Obesity Surgery · doi:10.1007/s11695-019-04201-y · Cited by 11
Wolver, S. E., Fadel, K., Fieger, E., Aburish, Z., O'Rourke, B., Chandler, T.-M., Shimotani, D., Clingempeel, N. L., Jain, S., Jain, A., et al. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.690855 · Cited by 15
Stroke in the Patient With Type 2 Diabetes
Jerkins, T. W., & Bell, D. S. H. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.01.010 · Cited by 11
Clinical course of adolescents with type 2 diabetes mellitus: A nationwide cohort study in Taiwan
Yen, F., Wei, J. C., Liu, J., Hsu, C., & Hwu, C. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13873 · Cited by 9
Anyanwagu, U., Donnelly, R., & IDRIS, I. R. (2018) · Kidney Diseases · doi:10.1159/000493731 · Cited by 10
Anyanwagu, U., Donnelly, R., & IDRIS, I. R. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy258 · Cited by 10
Gitt, A. K., Bramlage, P., Schneider, S., & Tschöpe, D. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0172-9 · Cited by 12
Effectiveness of insulin therapy in people with Type 2 diabetes in the Hoorn Diabetes Care System
Mast, M. R., Walraven, I., Hoekstra, T., Jansen, A. P. D., van der Heijden, A. A. W. A., Elders, P. J. M., Heine, R. J., Dekker, J. M., Nijpels, G., & Hugtenburg, J. G. (2016) · Diabetic Medicine · doi:10.1111/dme.13110 · Cited by 9
The current schemes of insulin therapy: Pro and contra
Riddle, M. C. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108817 · Cited by 15
Worldwide epidemiology of diabetes-related end-stage renal disease, 2000–2015
Cheng, H., Xu, X., Lim, P., & Hung, K. (2020) · doi:10.2337/figshare.13105469.v1 · Cited by 9
Boddepalli, C. S., Gutlapalli, S. D., Lavu, V. K., Abdelwahab, R. A. M., Huang, R., Potla, S., Bhalla, S., AlQabandi, Y., Nandula, S. A., & Khan, S. (2022) · Cureus · doi:10.7759/cureus.32286 · Cited by 12
Biomarker Signatures Predicting 10-Year All-Cause and Disease-Specific Mortality
Lu, Y., Monaco, G., Camous, X., Andiappan, A. K., Rötzschke, O., Ng, T. P., & Larbi, A. (2018) · The Journals of Gerontology Series A · doi:10.1093/gerona/gly138 · Cited by 8
Xu, S., Wang, B., Liu, W., Wu, C., & Huang, J. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-1911 · Cited by 8
Gabler, M., Picker, N., Geier, S., Foersch, J., Aberle, J., Martin, S., Riedl, M., & Wilke, T. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108734 · Cited by 9
Kuo, C., Kuo, N.-R., Yeh, Y., Lee, Y., Chuang, L., Chen, H.-F., Chen, C., Lee, C., Hsu, C., Li, H., et al. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-023-02001-z · Cited by 8
Bell, K. F., Parasuraman, S. V., Raju, A., Shah, M. B., Graham, J., & Denno, M. S. (2015) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2015.21.3.220 · Cited by 7
Risk factors of death in diabetes mellitus
Asfandiyarova, N. S. (2016) · Clinical Medicine (Russian Journal) · doi:10.18821/0023-2149-2016-94-9-697-700 · Cited by 7
Jung, I., Kwon, H., Park, S. E., Han, K.-D., Park, Y. G., Rhee, E., & Lee, W. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.1046 · Cited by 8
Wilkinson, S., Tomlinson, L. A., Iwagami, M., Stirnadel-Farrant, H. A., Smeeth, L. L., & Douglas, I. (2018) · Wellcome Open Research · doi:10.12688/wellcomeopenres.14660.1 · Cited by 7
Currie, C. J., & Holden, S. E. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12349 · Cited by 6
Self-citationKostev, K., Pscherer, S., Rist, R., Busch, S., & Scheerer, M. F. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816688011 · Cited by 6
Leal, J., Wellman, S. S., Jiranek, W. A., Seyler, T. M., Bolognesi, M. P., & Ryan, S. P. (2024) · The Journal of Arthroplasty · doi:10.1016/j.arth.2024.02.069 · Cited by 5
Arnold, S. V., McGuire, D. K., Spertus, J. A., Tang, F., Yue, P., Inzucchi, S. E., Belardinelli, L., CHAITMAN, B. R., & Kosiborod, M. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.07.025 · Cited by 5
Type 2 diabetes therapeutic strategies: why don't we see the «ELEPHANT» in the room?
Levit, S., Giveon, S. M., Philippov, Y. I., Domuschiev, I., & Zivony, A. (2016) · Diabetes Mellitus · doi:10.14341/dm7077 · Cited by 5
Altered Mental Status in the Solid-Organ Transplant Recipient
Weiss, N., Pflugrad, H., & Kandiah, P. (2024) · Seminars in Neurology · doi:10.1055/s-0044-1789004 · Cited by 4
Mortality risk in admitted patients with diabetes mellitus according to treatment
Akirov, A., Dicker, D., Shochat, T., & Shimon, I. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.04.011 · Cited by 4
Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease
Yagyu, H., & Shimano, H. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13859 · Cited by 4
Kwon, S., Ha, J. H., Kim, D. K., Kim, Y. S., Lim, C. S., Chang, H., Lee, J. P., & Park, J. (2021) · International Wound Journal · doi:10.1111/iwj.14370 · Cited by 3
Metabolic Correction in Patients Sample with Diabetes: Clinical Outcomes and Costs Reductions.
Miranda-Massari, J. R., Rodríguez-Gómez, J., González, M. J., Cidre, C., Duconge-Soler, J., Marín-Centeno, H., Grace, K., & McLeod, H. L. (2016) · PubMed · Cited by 4
Kent, D. J., McMahill‐Walraven, C. N., Panozzo, C. A., Pawloski, P. A., Haynes, K., Marshall, J. H., Brown, J. S., Eichelberger, B., & Lockhart, C. M. (2019) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2019.19042 · Cited by 5
The Prognostic Importance of Impaired Fasting Glycemia in Chronic Coronary Heart Disease Patients
Slezák, D., Mayer, O., Bruthans, J., Seidlerová, J., Rychecká, M., Gelžinský, J., Mateřánková, M., Karnosová, P., Wohlfahrt, P., Cífková, R., et al. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0684-9601 · Cited by 5
Mishriky, B. M., Cummings, D. M., Tanenberg, R. J., & Pories, W. J. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1533381 · Cited by 6
Efficacy and Cardiovascular Safety of Antidiabetic Medications
Pappachan, J. M. (2021) · Current Drug Safety · doi:10.2174/1574886316666210112153429 · Cited by 6
Technology-driven diabetes care: innovation without equity?
Salomon, I., & Sam, S. (2026) · Frontiers in Digital Health · doi:10.3389/fdgth.2026.1783456 · Cited by 3
Zuo, W., & Yang, X. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1493984 · Cited by 4
Weng, J., & Yang, X. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12082 · Cited by 3
Conroy, L., McCann, A., Zhang, N., & de Gaetano, M. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00695.2023 · Cited by 5
Levit, S., Philippov, Y. I., Cohen, O., Weichman, M., Azuri, J., Manisteski, Y., & Levit, V. M. (2015) · Diabetes Mellitus · doi:10.14341/dm2015170-77 · Cited by 3
Diabetes and the Cardiovascular System
Rigato, M., Fadini, G. P., & Avogaro, A. (2019) · Endocrinology · doi:10.1007/978-3-319-27316-7_6-3 · Cited by 3
McLean, R. C., & Logue, J. (2014) · Current Nutrition Reports · doi:10.1007/s13668-014-0105-3 · Cited by 3
Min, J. Y., Hackstadt, A. J., Griffin, M. R., Greevy, R. A., Chipman, J., Grijalva, C. G., Hung, A. M., & Roumie, C. L. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13846 · Cited by 3
Insulin/IGF signaling in islet biology and its therapeutic implications
Kim, H., & Kulkarni, R. N. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag014 · Cited by 2
Rajput, R., Mukherjee, J. J., Ayyar, V. S., & Ghosal, S. (2018) · Clinical Diabetology · doi:10.5603/dk.2018.0024 · Cited by 2
Insulin resistance: Unsolved issues of harm and use
Belik, E. V., & Gruzdeva, O. V. (2020) · Сибирский журнал клинической и экспериментальной медицины · doi:10.29001/2073-8552-2019-34-4-39-48 · Cited by 3
Leal, J., Wellman, S. S., Jiranek, W. A., Seyler, T. M., Bolognesi, M. P., & Ryan, S. P. (2024) · Orthopedics · doi:10.3928/01477447-20240619-02 · Cited by 2
Diabetes, Palliative and End-of-Life Care
Dunning, T. L. (2017) · InTech eBooks · doi:10.5772/67192 · Cited by 3
Risk factors associated with peripheral neuropathy among diabetic individuals: a case control study
Kingston, C., Aravindan, J., & Walsalam, S. (2021) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20210236 · Cited by 1
(2013) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2013.4.0171 · Cited by 2
Universiti Teknologi, M. A. R. A., YAHYA, N. S., AWANG, A., Nordin, R., & Universiti Teknologi, M. A. R. A. (2023) · Journal of Sustainability Science and Management · doi:10.46754/jssm.2023.06.007 · Cited by 1
Chen, M., Lin, L.-Y., Hung, T., Lin, T., Li, C., Lin, T., Chen, Y., Liou, J., & Wang, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70157 · Cited by 1
Kizza, N. R., Bukke, S. P. N., Yahaya, U.-K. H., & Bot, Y. S. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1735314 · Cited by 4
Kardiovaskuläre Effekte von Metformin, Sulfonylharnstoffen und Gliniden
Forst, T. M. (2016) · Der Diabetologe · doi:10.1007/s11428-016-0082-9 · Cited by 1
Does Metformin Have an Effect on Stent Patency Rates
Kibrik, P., Alsheekh, A. A., Izakovich, T., Chait, J., Goldstein, M. A., Monteleone, C. M., Hingorani, A., & Ascher, E. (2019) · Vascular and Endovascular Surgery · doi:10.1177/1538574419849999 · Cited by 1
Kim, S. S., & Kim, I. J. (2021) · Stroke revisited · doi:10.1007/978-981-16-5123-6_9 · Cited by 1
Poureskandari, M., Vahdati, S. S., Sadeghi‐Hokmabadi, E., Gholzari, S., Avval, N. A., & Ala, A. (2023) · International Journal of Drug Research in Clinics · doi:10.34172/ijdrc.2023.e6 · Cited by 2
Mortality in older people with diabetes: A review of current research
Forbes, A. (2017) · International Diabetes Nursing · doi:10.1080/20573316.2017.1352144 · Cited by 1
Schrijnders, D. (2019) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.103517830 · Cited by 1
Worldwide epidemiology of diabetes-related end-stage renal disease, 2000–2015
Cheng, H., Xu, X., Lim, P., & Hung, K. (2020) · doi:10.2337/figshare.13105469 · Cited by 1
Cardiovascular Risk in Diabetes Mellitus: Cause and Effect
Pollack, C. V., Ford, W. T., Volturo, G., Badlani, S., Yu, D. J., & Brogan, G. X. (2013) · Current Emergency and Hospital Medicine Reports · doi:10.1007/s40138-013-0034-2
Le diabète de type 2 au stade de l’insuline : Quelle place pour les inhibiteurs de la DPP-4 ?
Halimi, S., Charbonnel, B. H., Monguillon, P., & Dejager, S. (2015) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(15)30011-0 · Cited by 1
Insulin, Other Hypoglycaemic Drugs, and Glucagon
Bavec, A. (2014) · Side effects of drugs annual · doi:10.1016/b978-0-444-63407-8.00042-3 · Cited by 1
Nur Metformin bessert Überlebensraten
Siegmund, T. (2016) · Info Diabetologie · doi:10.1007/s15034-016-0826-z
Besser kein Insulin für Menschen mit Typ-2-Diabetes?
Arand, M. (2015) · Info Diabetologie · doi:10.1007/s15034-015-0684-0
After Metformin, What Comes Next? Empagliflozin?
Zinman, B., & Nichols, G. A. (2015)
Mitchell, A., Price, M., & Cipriano, G. C. (2021) · medRxiv · doi:10.1101/2021.06.04.21258310
Imai, K., Murayama, H., & Hirose, T. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0476-3
Diabetes and the Cardiovascular System
Rigato, M., Fadini, G. P., & Avogaro, A. (2018) · Endocrinology · doi:10.1007/978-3-319-27316-7_6-1
INSUFICIENCIA CARDÍACA Y DIABETES
Panzitta, M. C., & Sinay, I. R. (2018) · Revista de la Sociedad Argentina de Diabetes · doi:10.47196/diab.v52i1.85 · Cited by 1
Thérapeutique des désordres glycémiques
Monnier, L., & Colette, C. (2014) · Elsevier eBooks · doi:10.1016/b978-2-294-73954-5.00007-x
SOP Einstellung mit Insulin in der Hausarztpraxis
Uebel, T. (2020) · Allgemeinmedizin up2date · doi:10.1055/a-1190-7945
Glucose metabolism in cancer: heterogeneity and potentials for targeting in patients
Hendriks, A. M. (2021) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.178801097
Thérapeutique des désordres glycémiques
(2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00007-5
Diabetes and the Cardiovascular System
Rigato, M., Fadini, G. P., & Avogaro, A. (2018) · Endocrinology · doi:10.1007/978-3-319-44433-8_6
Diabetes and the Cardiovascular System
Rigato, M., Fadini, G. P., & Avogaro, A. (2020) · Endocrinology · doi:10.1007/978-3-030-36694-0_6
Diabetes and the Cardiovascular System
Rigato, M., Fadini, G. P., & Avogaro, A. (2019) · Endocrinology · doi:10.1007/978-3-319-27316-7_6-2
Li, X., Ge, Y., Chai, S., Wan, Y., Xia, H., Ren, X., Yuan, H., Hou, Q., & Yang, J. (2022) · Research Square · doi:10.21203/rs.3.rs-1490913/v1
La terapia insulinica nel diabete mellito di tipo 2
Toffalini, A., Mantovani, A., & Zoppini, G. (2022) · il Diabete · doi:10.30682/ildia2201b
Eriş, D. (2023) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.2576
Outcomes of PCI of all comers: the experience of a Kuwaiti independent healthcare institution
Mudawi, T. O., Alenezi, W., Amin, A., Besada, D., Aly, A., Fathi, A., Khdair, D. A., & Alanbaei, M. (2024) · British Journal of Cardiology · doi:10.5837/bjc.2024.016
Flavonoids and Nanotechnology in Insulin Resistance Diabetic Complications
Kumar, S., Singh, M., Murkute, P. S., Chakraborty, A., Farid, A., Kiani, H. S., Taghizadeh‐Hesary, F., Bhowmick, M., & Ashique, S. (2024) · Wiley eBooks · doi:10.1002/9781394238071.ch8 · Cited by 1
Elkassem, S. (2025) · European surgery. Supplement/European surgery · doi:10.1007/s10353-025-00858-1
Yen, F., Wei, J. C.-C., Huang, Y., Li, P.-Y., Tsai, F., Hsu, C.-C., & Hwu, C. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112328
Ekström, N. (2014) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Kuo, C.-S., Kuo, N.-R., Yeh, Y.-K., Lee, Y.-J., Chuang, L.-M., Chen, H.-F., Chen, C.-C., Lee, C.-C., Hsu, C.-C., Li, H.-Y., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25052343
Kuo, C.-S., Kuo, N.-R., Yeh, Y.-K., Lee, Y.-J., Chuang, L.-M., Chen, H.-F., Chen, C.-C., Lee, C.-C., Hsu, C.-C., Li, H.-Y., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25052462
Effect of Glucose Management on Coronary Heart Disease Risk in Patients With Type 2 Diabetes
Lipska, K. J., & Inzucchi, S. E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00010-0
Metadata
- Authors
- Currie, C. J., Poole, C. D., Evans, M., Peters, J. R., & Morgan, C. L.
- Affiliations
- Cardiff University (GB)
- University Hospital of Wales (GB)
- Corresponding author
- Currie, Craig J.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2013-02-01
- Volume
- 98
- Issue
- 2
- Pages
- 668-677
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC3612791
- OpenAlex
- W2157836715
- Cited by
- 203
- References
- 38
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 9 · 2023: 5 · 2022: 7 · 2021: 15 · 2020: 17 · 2019: 15 · 2018: 25 · 2017: 18 · 2016: 26 · 2015: 23 · 2014: 19 · 2013: 12
- FWCI
- 21.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, insulin monotherapy, metformin, major adverse cardiac events, myocardial infarction, stroke, cancer risk, mortality, microvascular complications, renal complications, HbA1c, adverse drug reactions, primary care patients
- MeSH terms
- Adult, Aged, Aged, 80 and over, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Prognosis, Retrospective Studies, Risk, Sulfonylurea Compounds, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.